«Влияние терапии бозентаном на клиническое состояние, гемодинамический статус, выраженность процессов ремоделирования правых и левых отделов сердца у больных с идиопатической легочной гипертензией» (стр. 24 )

10. Battistini B., Dussault P. Blocking of the endothelin system: the development of receptor antagonists. Pulm Pharmacol Ther 1998; 11:97–112.

11. Beard J. T., Byrd B. F. Saline contrast enhancement of trivial Doppler tricuspid regurgitation signals for estimating pulmonary artery systolic pressure. Am J Cardiol 1988; 62:486-488.

12. Bech-Hanssen O., Karason K., Rundqvist B., et al. Can pulmonary hypertension and increased pulmonary vascular resistance be ruled in and ruled out by echocardiography? J Am Soc Echocardiogr. 2013 May;26(5):469-78.

13. Boilson B. A., Pislaru S. V., McGregor C. G. Accuracy of echocardiographic assessment of pulmonary hypertension severity and right ventricular dysfunction in patients with chronic thromboembolic pulmonary hypertension. Minerva Cardioangiol. 2012 Jun;60(3):257-65.

14. Boulanger C., Luscher T. F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587–590.

15. Brierre G., Blot-Souletie N., Degano B., et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. Eur J Echocardiogr 2010; 11:516–522.

16. Rostagno C. Calcium-Channel Blockers in Primary Pulmonary Hypertension. N Engl J Med 1992; 327:1458-1459.

17. Channick R. N., Newhart J. W., Johnson F. W., et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. Chest 1996; 109:1545–1549.

18. Channick R. N., Yung G. L. Long-term use of inhaled niric oxide for pulmonary hypertension. Respir Care 1999; 44:212–219.

19. Cho I. J., Oh J., Chang H. J., et al. Tricuspid regurgitation duration correlates with cardiovascular magnetic resonance-derived right ventricular ejection fraction and predict prognosis in patients with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. 2013 May 22.

20. Currie P. J., Seward J. B., Chan K. L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985 Oct;6(4):750-6.

21. Dalen H., Thorstensen A., Vatten L. J. et al. Reference Values and Distribution of Conventional Echocardiographic Doppler Measures and Longitudinal Tissue Doppler Velocities in a Population Free From Cardiovascular Disease. Circ Cardiovasc Imaging. 2010;3:614-622.

22. D'Alonzo G. E., Barst R. J., Ayres S. M., et rvival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.

23. Davie N., Haleen S. J., Upton P. D., et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165:398–405.

24. Dini F. L., Galderisi M., Mondilo S., et al. The right ventricle: role of doppler echocardiography in clinical practice. Ital Heart J Suppl. 2004 Oct;5(10):757-69.

25. Dong F., Zhang X., Wold L. E., et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase andcaveolin-1. Br J Pharmacol 2005; 145:323–333.

26. Drighil A., Madias J. E., Mathewson J. W. et al. Haemodialysis: effects of acute decrease in preload on tissue Doppler imaging indices of systolic and diastolic function of the left and righr ventricles. European J of Echocardiography (2008) 9,530-535.

27. Dupuis J., Jasmin J. F., Priй S., et al. Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther. 2000;13(3):135-40.

28. Dupuis J., Stewart D. J., Cernacek P., et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94:1578–1584.

29. Fisher MR, Forfia PR, Chamera E. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009 Apr 1;179(7):615-21.

30. Forfia P. R., Fisher M. R., Mathai S. C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174:1034–1041.

31. Galiи N., Hoeper M. M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34:1219–1263.

32. Galie` N., Hinderliter A., Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:1380–1386.

33. Gardin J. M., Davidson D. M., Rohan M. K., et al. Relationship between age, body size, gender, and blood pressure and Doppler flow measurements in the aorta and pulmonary artery. Am Heart J. 1987 Jan;113(1):101-9.

34. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214–221.

35. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732–1739.

36. Goldie R. G., D’Aprile A. C., Self G. J., et al. The distribution and density of receptor subtypes for endothelin-1 in peripheral lung of the rat, guinea-pig and  pig. Br J Pharmacol 1996; 117:729–735.

37. Gomez A., Bialostozky D., Zajarias A., et al. Right ventricular ischemia in patients with

primary pulmonary hypertension. J Am Coll Cardiol 2001;38:1137–1142.

38. Grossman W., Barry W. Cardiac Catheterization. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders; 1988:247–252.

39. Lawrence G. R., Wyman W. Lai, Jonathan A., et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713.

40. Habib G., Torbicki A. The role of echocardiography in the diagnosis and management of patients with pulmonary hypertension. Eur Respir Rev. 2010 Dec;19(118):288-99.

41. Hatano S., Strasser T. World Health Organization 1975. Primary pulmonary hypertension. Geneva: WHO; 1975.

42. Himelman R. B., Struve S. N., Brown J. K., et al. Improved recognition of cor pulmonale in patients with severe chronic obstructive pulmonary disease. Am J Med. 1988 May;84(5):891-8.

43. Hinderliter A. L., Willis P. W. 4th, Long W., et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol 1999; 84:481–484.

44. Hirata Y., Emori T., Eguchi S., et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91:1367–1373.

45. Hocher B., Schwarz A., Fagan K. A., et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23:19–26.

46. Hoeper M. M., Lee S. H., Voswinckel R., et plications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48:2546 –2552.

47. Humbert M., Morrell N. W., Archer S. L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S13-S24.

48. Humbert M., Segal E. S., Kiely D. G., et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30:338–344.

49. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.

50. Isobe M., Yazaki Y., Takaku F., et al.  Prediction of pulmonary arterial pressure in adults by pulsed Doppler echocardiography. Am J Cardiol. 1986 Feb 1;57(4):316-21.

51. Javed U., Balasubramanian V.,  Ralph J. W. et al. Correlation of right ventricular tissue doppler imaging with invasive hemodynamics in pulmonary hypertension.  Chest. 2009;136:31S.

52. Karamanoglu M., McGoon M., Frantz R. P.; Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest. 132 2007:37-43.

53. Kaul S., Tei C., Hopkins J. M., et al. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984;107:526-31.

54. Kaya M. G., Lam Y. Y., Erer B., et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012 May;18(5):379-84.

55. Kepez A., Sunbul M., Kivrak T., et al. Evaluation of Improvement in Exercise Capacity after Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension: Correlation with Echocardiographic Parameters. Thorac Cardiovasc Surg. 2013 Apr 5.

56. Kitabatake A., Inoue M., Asao M., et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983 Aug;68(2):302-9.

57. Klob J., Wochenblatt of the K. K. Doctors in Vienna 1865, 357–61.

58. Knott P. G., D’Aprile A. C., Henry P. J., et al. Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 1995; 114:1–3.

59. Kouyoumdjian C. Continuous inhalation of nitric oxide protects against development of

pulmonary hypertension in chronically hypoxic rats. J Clin Invest 1994; 94: 578–584.

60. Kowalski M., Kukulski T., Jamal F. et al. Can natural strain and strain rate quantify regional myocardial deformation? A study in healthy subjects. Ultrasound Med /biol. 2001 Aug;27(8):1087-97.

61. Kuhn K. P., Byrne D. W., Arbogast P. G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167:580–586.